AI Article Synopsis
- The study assessed the use of [123I]FP-CIT SPECT imaging to measure dopaminergic degeneration in early-stage Parkinson's Disease (PD) patients over a mean span of 12 months.
- The results indicated an average annual decrease of about 8% in [123I]FP-CIT binding ratios, suggesting a measurable rate of degeneration.
- To effectively detect significant neuroprotective effects in clinical trials, around 36 patients would be needed in each group, making [123I]FP-CIT SPECT a promising method for tracking PD progression and therapy effectiveness.
Article Abstract
We investigated the applicability [123I]FP-CIT SPECT for the assessment of the rate of dopaminergic degeneration in PD. Twenty early-stage PD patients (age range 43-73 yr; mean age 55.4) were examined twice, a mean of 12 months apart. The mean annual change in the ratio of specific to nonspecific [123I]FP-CIT binding to the striatum was used as the outcome measure. The mean annual decrease in striatal [123I]FP-CIT binding ratios was found to be about 8% (of the baseline mean). In order to demonstrate a significant effect (p < 0.05) of putative neuroprotective agent with 0.80 power and 50% of predicted protection within 2 years, 36 patients are required in each group, when the effects are measured by means of changes in [123I]FP-CIT binding ratios in whole striatum. Our findings indicate that [123I]FP-CIT SPECT seems to be a useful tool to investigate the progression of dopaminergic degeneration in PD and may provide an objective method of measuring the effectiveness of neuroprotective therapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s007020170019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neural substrates underlying distinct dual cognitive syndromes in Parkinson's disease.
Eur J Neurol
January 2025
Department of Human Health Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Background: A dual-syndrome hypothesis, which states the cognitive impairments in Parkinson's disease (PD) are attributable to frontostriatal dopaminergic dysregulation and cortical disturbance-each associated with attention/executive and memory/visuospatial dysfunction, respectively-has been widely accepted. This multisystem contribution also underlies highly heterogeneous progression rate to dementia.
Methods: Nondemented PD patients who underwent [I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) nortropane ([I]FP-CIT) SPECT and neuropsychological examinations were enrolled.
Exploring the relation between REM sleep behavior disorder onset and striatal dopaminergic dysfunction in Parkinson's Disease.
J Neurol
December 2024
Department "G.F. Ingrassia", Section of Neurosciences, University of Catania, Via Santa Sofia 78, 95123, Catania, Italy.
Article Synopsis
- The study investigates two phenotypes of Parkinson's Disease (PD) based on the timing of REM sleep behavior disorder (RBD) onset in relation to motor symptoms: "body first" (RBD before motor symptoms) and "brain first" (RBD after motor symptoms).
- Researchers analyzed striatal dopaminergic function in PD patients using imaging and found that the "body first" group exhibited more symmetrical motor impairment, higher cognitive decline, and distinctive imaging results compared to those with later onset RBD.
- The findings corroborate the SOC model's predictions, indicating different patterns of neurological function and cognitive impairment linked to the onset of RBD in PD.
Reliable diagnosis of nigrostriatal degeneration by dopamine transporter SPECT despite drug interaction with venlafaxine or bupropion.
Eur J Nucl Med Mol Imaging
November 2024
Department of Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Purpose: This study examined the impact of venlafaxine and bupropion on the detection of nigrostriatal degeneration by dopamine transporter (DAT)-SPECT.
Methods: 43 patients (70.7 ± 8.
Dopaminergic PET to SPECT domain adaptation: a cycle GAN translation approach.
Eur J Nucl Med Mol Imaging
February 2025
Department of Nuclear Medicine / PET Center, Huashan Hospital, Fudan University, Shanghai, 200235, China.
Purpose: Dopamine transporter imaging is routinely used in Parkinson's disease (PD) and atypical parkinsonian syndromes (APS) diagnosis. While [C]CFT PET is prevalent in Asia with a large APS database, Europe relies on [I]FP-CIT SPECT with limited APS data. Our aim was to develop a deep learning-based method to convert [C]CFT PET images to [I]FP-CIT SPECT images, facilitating multicenter studies and overcoming data scarcity to promote Artificial Intelligence (AI) advancements.
View Article and Find Full Text PDFOptimal DaTQUANT Thresholds for Diagnostic Accuracy of Dementia with Lewy Bodies (DLB) and Parkinson's Disease (PD).
Tomography
October 2024
Statistics Consulting Laboratory, BIO5 Institute, University of Arizona, Tucson, AZ 85719, USA.
Quantitative thresholds are helpful to define an abnormal DaT SPECT in patients with suspected nigrostriatal degenerative diseases (NSDD). The optimal DaTQUANT threshold for diagnostic accuracy of DaT SPECT across combined movement and cognitive disorder populations has been previously described. : We established optimal DaTQUANT thresholds that enhance the discrimination between dementia with Lewy bodies (DLB) and non-DLB dementia types, as well as between Parkinsonian syndromes (PS) and conditions not characterized by nigrostriatal degeneration (non-PS).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!